POSTMENOPAUSAL OSTEOPOROSIS

以腰椎骨密度变化为指标，比较阿仑磷酸钠70 mg/周、35 mg/周和10 mg/d治疗1年后绝经后骨质疏松症的疗效。目的：评价绝经后骨质疏松症患者每周服用阿仑磷酸钠70 mg，每周2次服用35 mg，与每日服用10 mg相比，1年的安全性和耐受性。目的：通过观察绝经后骨质疏松症患者髋部(全髋关节、股骨颈、粗隆)和全身骨密度的变化，比较阿仑磷酸钠70 mg/周、35 mg/周和10 mg/d治疗1年后的疗效。目的：通过生化标记物(NTX和BSAP)对绝经后骨质疏松症患者骨转换率的影响，评价阿仑磷酸钠每日10 mg治疗1年的效果。目的：评价每周服用70 mg阿伦磷酸钠和每周两次服用阿伦磷酸钠35 mg与每日服用阿伦磷酸钠10 mg治疗2年对腰椎、髋部(全髋关节、股骨颈和粗隆)及全身骨密度的影响；用生化标记物(NTX和BSAP)评估骨转换率；以及对绝经后骨质疏松妇女的安全性和耐受性。

To compare the effects of 1 year of treatment with alendronate 70 mg once weekly and 35 mg twice weekly with treatment with 10 mg daily in post- menopausal women with osteoporosis as measured by changes in BMD at the lumbar spine. To assess the safety and tolerability of 1 year of treatment with alendronate 70 mg once weekly and 35 mg twice weekly compared to treatment with 10 mg daily in postmenopausal women with osteoporosis. To compare the effects of 1 year of treatment with alendronate 70 mg once weekly and 35 mg twice weekly with treatment with 10 mg daily in postmenopausal women with osteoporosis as measured by changes in BMD at the hip (total hip, femoral neck, and trochanter) and total body. To assess the effect of 1 year of treatment with alendronate 10 mg daily on the rate of bone turnover as assessed by biochemical markers (NTx and BSAP) in postmenopausal women with osteoporosis. To assess the effect of 2 years of treatment with alendronate 70 mg once weekly and alendronate 35 mg twice weekly comapared to treatment with alendronate 10 mg daily on BMD at the lumbar spine, hip (total hip,femoral neck, and trochanter), and total body; the rate of bone turnover as assessed by biochemical markers (NTx and BSAP); and the safety and tolerability in postmenopausal women with osteoporosis